Standard Contracts
AMENDMENT NO. 1 TO MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • November 12th, 2019 • IVERIC Bio, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 12th, 2019 Company IndustryThis Amendment No. 1 to the Master Sponsored Research Agreement (“Agreement”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104-4310, and IVERIC bio, Inc. (formerly Ophthotech Corporation), a Delaware corporation (“Sponsor”), having a place of business at One Penn Plaza, Suite 3520, New York, NY 10119 is dated as of October 1, 2019 (the “Amendment No. 1 Effective Date”). Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.
EX-10.8 7 d772541dex108.htm MASTER SPONSORED RESEARCH AGREEMENT [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the...Master Sponsored Research Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis Agreement (“Agreement”), effective as of the date of November 21, 2013 (“Effective Date”), is between Memorial Sloan-Kettering Cancer Center, a New York not-for-profit corporation with a principal office at 1275 York Avenue, New York, NY 10065 (“MSKCC”) and Juno Therapeutics, Inc., a Delaware corporation with a principal office at 8725 W. Higgins Road, Suite 290, Chicago, IL 60631 (“Sponsor”). MSKCC and Sponsor will be individually a “Party” and collectively, the “Parties.”
Master Sponsored Research Agreement – What To Expect . . .Master Sponsored Research Agreement • December 18th, 2017
Contract Type FiledDecember 18th, 2017A master sponsored research agreement (Master) is used to facilitate a long-term strategic relationship with a company that funds ISU research on a frequent basis by streamlining the negotiation process. The approved terms are applied to every project performed under the Master without the need to negotiate. Individual projects are implemented through a project exhibit sometimes referenced by ISU as “Exhibit A.”
MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • August 8th, 2023 • Immunome Inc. • Pharmaceutical preparations • Indiana
Contract Type FiledAugust 8th, 2023 Company Industry JurisdictionThis Master Sponsored Research Agreement (“Agreement”), made as of February 1, 2022 (“Effective Date”), by and among MorphImmune, Inc (“COMPANY” or “Sponsor” or “Company”), a corporation having its principal place of business at 1281 Win Hentschel Blvd. Suite 1300, West Lafayette, IN 47906; Purdue Research Foundation (“PRF”) 1281 Win Hentschel Blvd., West Lafayette, Indiana 47906; and Purdue University (“Purdue” or “University”), 610 Purdue Mall, West Lafayette, Indiana 47907-2040, (each a “Party” and collectively, the “Parties”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. MASTER SPONSORED RESEARCH...Master Sponsored Research Agreement • August 1st, 2019 • IVERIC Bio, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 1st, 2019 Company Industry JurisdictionThis Master Sponsored Research Agreement (“Agreement”) is dated as of October 30, 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6283, and Ophthotech Corporation, a Delaware corporation (“Sponsor”), having a place of business at One Penn Plaza, Suite 3520, New York, NY 10119. Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.
THIRD AMENDMENT TO MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • September 24th, 2009 • Neurologix Inc/De • Pharmaceutical preparations • Ohio
Contract Type FiledSeptember 24th, 2009 Company Industry JurisdictionThis Third Amendment, dated as of September 24, 2009 (this “Third Amendment”), by and between THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, on behalf of Ohio State University, a university with a principal place of business at 1960 Kenny Road, Columbus, OH 43210 (“Institution”), and NEUROLOGIX, INC., a Delaware corporation with a principal place of business at One Bridge Plaza, Fort Lee, New Jersey, 07024 (“Sponsor”).
SECOND AMENDMENT TO MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • December 16th, 2008 • Neurologix Inc/De • Pharmaceutical preparations • Ohio
Contract Type FiledDecember 16th, 2008 Company Industry JurisdictionThis Second Amendment, dated as of October 29, 2008 (this “Second Amendment”), by and between THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, on behalf of Ohio State University, a university with a principal place of business at 1960 Kenny Road, Columbus, OH 43210 (“Institution”), and NEUROLOGIX, INC., a Delaware corporation with a principal place of business at One Bridge Plaza, Fort Lee, New Jersey, 07024 (“Sponsor”).
AMENDMENT NO. 2 TO MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • August 4th, 2021 • IVERIC Bio, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 4th, 2021 Company IndustryThis Amendment No. 2 to the Master Sponsored Research Agreement (“Amendment No. 2”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104-4310, and IVERIC bio Gene Therapy LLC (successor-in-interest to IVERIC bio, Inc., One Penn Plaza, Suite 3520, New York, NY 10119.), a Delaware limited liability company (“Sponsor”), having a place of business at Five Penn Plaza, Suite 2372, New York, NY 10001 is dated as of May 18, 2021 (the “Amendment No. 2 Effective Date”). Penn and Sponsor may be referred to herein as a “Party” or, collectively, as “Parties”.
FOURTH AMENDMENT TO MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • January 20th, 2011 • Neurologix Inc/De • Pharmaceutical preparations • Ohio
Contract Type FiledJanuary 20th, 2011 Company Industry JurisdictionThis Fourth Amendment, dated as of January 18, 2011 (this “Fourth Amendment”), by and between THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, on behalf of Ohio State University, a university with a principal place of business at 1960 Kenny Road, Columbus, OH 43210 (“Institution”), and NEUROLOGIX, INC., a Delaware corporation with a principal place of business at One Bridge Plaza, Fort Lee, New Jersey, 07024 (“Sponsor”).
MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • October 8th, 2020 • Y-mAbs Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 8th, 2020 Company Industry JurisdictionThis Master Sponsored Research Agreement (this “Agreement”), effective as of the date of the last signature below (“Effective Date”), is by and between Memorial Sloan Kettering Cancer Center, a New York not-for-profit entity, with offices at 1275 York Avenue, New York, NY 10065 (“MSK”) and Y-mAbs Therapeutics, Inc., a Delaware corporation with a principal office at 230 Park Avenue, Suite 3350, New York, New York 10169 (“Sponsor”). MSK and Sponsor may be individually referred to as a “Party”, and collectively as the “Parties”.
AMENDMENT TO MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • June 11th, 2008 • Neurologix Inc/De • Pharmaceutical preparations • Ohio
Contract Type FiledJune 11th, 2008 Company Industry JurisdictionAmendment, dated as of May 29th, 2008 (this “Amendment”), by and between THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION, on behalf of Ohio State University, a university with a principal place of business at 1960 Kenny Road, Columbus, OH 43210 (“Institution”), and NEUROLOGIX, INC., a Delaware corporation with a principal place of business at One Bridge Plaza, Fort Lee, New Jersey, 07024 (“Sponsor”).
MASTER SPONSORED RESEARCH AGREEMENTMaster Sponsored Research Agreement • October 9th, 2015 • Wave Life Sciences Pte LTD • Pharmaceutical preparations • Pennsylvania
Contract Type FiledOctober 9th, 2015 Company Industry JurisdictionTHIS MASTER SPONSORED RESEARCH AGREEMENT (“Master Agreement”) is made and effective as of April 1, 2015 (the “Effective Date”), by and between WaVe Life Sciences PTE, Ltd with an office at 419 Western Avenue, Boston, Massachusetts, 02135 (“WaVe”), and The Children’s Hospital of Philadelphia, a Pennsylvania non-profit corporation with an office at 34th Street and Civic Center, Philadelphia, Pennsylvania 19104 (together with its affiliates “CHOP”). WaVe and CHOP are each hereafter referred to individually as a “Party” and together as the “Parties.”